ICIs that block PD-1/PD-L1 axis have demonstrated improvements in survival over chemotherapy alone in NSCLC in multiple randomized trials both when administered as individual agents (1–3) and as combination ICI regimens (4). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.